Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis

Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, Wood P, McLintock C

(2014), Intern Med J, 44(6), 525-36

Species-Specific Regulation of t-PA and PAI-1 Gene Expression in Human and Rat Astrocytes

Tjärnlund-Wolf A, Hultman K, Blomstrand F, Nilsson M, Medcalf RL, Jern C

(2014), Gene Regul Syst Bio, 8, 113-8

ZEB2-transgene expression in the epidermis compromises the integrity of the epidermal barrier through the repression of different tight junction proteins

Tatari MN, De Craene B, Soen B, Taminau J, Vermassen P, Goossens S, Haigh K, Cazzola S, Lambert J, Huylebroeck D, Haigh JJ, Berx G

(2014), Cell Mol Life Sci, 71(18), 3599-609

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C

(2014), Blood, 124(14), 2190-5

Differential signaling by protease-activated receptors: implications for therapeutic targeting

Sidhu TS, French SL, Hamilton JR

(2014), Int J Mol Sci, 15(4), 6169-83

N-Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo?

Shortt J, Opat SS, Wood EM

(2014), Transfusion, 54(9), 2362-3

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ

(2014), Blood, 123(26), 4136-42

Oxidation of an exposed methionine instigates the aggregation of glyceraldehyde-3-phosphate dehydrogenase

Samson AL, Knaupp AS, Kass I, Kleifeld O, Marijanovic EM, Hughes VA, Lupton CJ, Buckle AM, Bottomley SP, Medcalf RL

(2014), J Biol Chem, 289(39), 26922-36

A novel agent with histone deacetylase inhibitory activity attenuates neointimal hyperplasia

Rahmatzadeh M, Liu HB, Krishna SM, Gaspari TA, Welungoda I, Widdop RE, Dear AE

(2014), Cardiovasc Drugs Ther, 28(5), 395-406

Molecular cloning and characterization of rhesus monkey platelet glycoprotein Ibα, a major ligand-binding subunit of GPIb-IX-V complex

Qiao J, Shen Y, Shi M, Lu Y, Cheng J, Chen Y

(2014), Thromb Res, 133(5), 817-25

Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma

Pennings GJ, Yong AS, Wong C, Al-Tamimi M, Gardiner EE, Andrews RK, Kritharides L

(2014), Platelets, 25(8), 639-42

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M,

(2014), Lancet Oncol, 15(3), 333-42

Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?

Niego B, Medcalf RL

(2014), J Cereb Blood Flow Metab, 34(8), 1283-96

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton

Mithraprabhu S, Khong T, Spencer A

(2014), Cell Death Dis, 5, e1134

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A

(2014), Epigenetics, 9(11), 1511-20

A new form of macrothrombocytopenia induced by a germ-line mutation in the PRKACG gene

Manchev VT, Hilpert M, Berrou E, Elaib Z, Aouba A, Boukour S, Souquere S, Pierron G, Rameau P, Andrews R, Lanza F, Bobe R, Vainchenker W, Rosa JP, Bryckaert M, Debili N, Favier R, Raslova H

(2014), Blood, 124(16), 2554-63

Rab8a interacts directly with PI3Kγ to modulate TLR4-driven PI3K and mTOR signalling

Luo L, Wall AA, Yeo JC, Condon ND, Norwood SJ, Schoenwaelder S, Chen KW, Jackson S, Jenkins BJ, Hartland EL, Schroder K, Collins BM, Sweet MJ, Stow JL

(2014), Nat Commun, 5, 4407

Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies

Liu HB, Urbanavicius D, Tan P, Spencer A, Dear AE

(2014), Int J Oncol, 45(4), 1742-8

Incidence of venous thromboembolism in different ethnic groups: a regional direct comparison study

Liao S, Woulfe T, Hyder S, Merriman E, Simpson D, Chunilal S

(2014), J Thromb Haemost, 12(2), 214-9

Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm

Lamrani L, Lacout C, Ollivier V, Denis CV, Gardiner E, Ho Tin Noe B, Vainchenker W, Villeval JL, Jandrot-Perrus M

(2014), Blood, 124(7), 1136-45

365 366 367 368 369